Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Hydrotalcite is suitable for acute and chronic gastritis, reflux esophagitis, gastric and duodenal ulcers, stomach pain, heartburn, acid belching, fullness and other uncomfortable symptoms related to gastric acid. It is also used to prevent gastric mucosal damage caused by non-steroidal drugs. Hydrotalcite, developed by Bayer Pharmaceuticals in Germany was approved in China in 1996. As of 2020, in addition to the original research company, the main manufacturers in the Chinese Hydrotalcite market are Chongqing Pharscin Pharmaceutical Co., Ltd., Guangdong Huarun Shunfeng Pharmaceutical Co., Ltd., Ltd., Sichuan Jianneng Pharmaceutical Co., Ltd. and Hubei Ouly Pharmaceutical Co., Ltd.
According to CRI’s research market, the sales of Hydrotalcite in the Chinese market were generally stable from 2016 to 2019. The sales value of Hydrotalcite in the Chinese market decreased by 49.28% year on year because of the outbreak of the COVID-19 epidemic in 2020 and the effects of government procurement. The CAGR of China's Hydrotalcite sales value from 2016 to 2020 is -15.36%.
Researcher predicts that the sales of Hydrotalcite in China will have a restorative growth from 2021 to 2025 as the alleviation of the COVID-19 epidemic. In addition, in the context of an aging population and unhealthy lifestyles, the number of patients with gastrointestinal diseases in China will continue to increase, and the sales value and sales volume of Hydrotalcite used to treat acute and chronic gastroenteritis and other gastrointestinal diseases will increase. It is estimated that China's Hydrotalcite sales market by sales value will exceed CNY100 million.
Topics Covered:
-Development environment of Chinese Hydrotalcite market
-Governmental approval of Hydrotalcite in China
-Prices of Hydrotalcite in China
-Major Hydrotalcite manufacturers in China
-Factors influencing the development of Chinese Hydrotalcite market
-Prospects of Chinese Hydrotalcite market
According to CRI’s research market, the sales of Hydrotalcite in the Chinese market were generally stable from 2016 to 2019. The sales value of Hydrotalcite in the Chinese market decreased by 49.28% year on year because of the outbreak of the COVID-19 epidemic in 2020 and the effects of government procurement. The CAGR of China's Hydrotalcite sales value from 2016 to 2020 is -15.36%.
Researcher predicts that the sales of Hydrotalcite in China will have a restorative growth from 2021 to 2025 as the alleviation of the COVID-19 epidemic. In addition, in the context of an aging population and unhealthy lifestyles, the number of patients with gastrointestinal diseases in China will continue to increase, and the sales value and sales volume of Hydrotalcite used to treat acute and chronic gastroenteritis and other gastrointestinal diseases will increase. It is estimated that China's Hydrotalcite sales market by sales value will exceed CNY100 million.
Topics Covered:
-Development environment of Chinese Hydrotalcite market
-Governmental approval of Hydrotalcite in China
-Prices of Hydrotalcite in China
-Major Hydrotalcite manufacturers in China
-Factors influencing the development of Chinese Hydrotalcite market
-Prospects of Chinese Hydrotalcite market
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
